Development of Novel NCG-hIL15 and -hIL2 Mouse Models for Preclinical Assessment of Human NK Cell Function

Natural killer (NK) cells are critical effectors of innate antitumor immunity, yet conventional immunodeficient mouse models poorly support human NK cell engraftment and function. To overcome this limitation, GemPharmatech developed NCG-hIL2 and NCG-hIL15 humanized mouse models expressing human IL-2 or IL-15, respectively. Following reconstitution with human PBMCs or hematopoietic stem cells, both models markedly enhanced human NK cell development. Notably, the NCG-hIL15 model further enabled robust co-engraftment of T cells and NK cells. These models effectively supported the evaluation of NK cell-mediated immunotherapies, including antibody-dependent cellular cytotoxicity (ADCC)-inducing antibodies. Together, they provide valuable complementary platforms for studying human NK cell biology and advancing NK-based cancer immunotherapies.